Table 1 Baseline demographics and clinical characteristics
Characteristic | Clodronate (n = 530) | Placebo (n = 539) |
|---|---|---|
Mean age ± SD (years) | 52.8 ± 10.6 | 52.7 ± 10.5 |
Mean BMI ± SD (kg/m2) | 25.8 ± 4.5 | 25.8 ± 4.8 |
Menopausal status (n) | ||
Premenopausal | 265 (50%) | 265 (49%) |
Postmenopausal | 265 (50%) | 274 (51%) |
Axillary lymph node involvement (n) | 196 (37%) | 202 (38%) |
Tumor stage (n) | ||
I | 137 (26%) | 143 (26%) |
II | 304 (57%) | 305 (57%) |
III | 48 (9%) | 52 (10%) |
Unclassifiable | 40 (8%) | 39 (7%) |
Missing | 1 (0.2%) | 0 (0%) |
Hormone receptor status (n) | ||
Oestrogen receptor-positive | 245 (46%) | 240 (45%) |
Oestrogen receptor-negative | 136 (26%) | 136 (25%) |
Oestrogen receptor-unknown | 149 (28%) | 163 (30%) |
Progesterone receptor-positive | 112 (21%) | 116 (22%) |
Progesterone receptor-negative | 79 (15%) | 75 (14%) |
Progesterone receptor-unknown | 339 (64%) | 348 (65%) |